Humana Wegovy and Zepbound Coverage for Medicare Advantage Members
Most Humana Medicare Advantage plans exclude weight-loss drugs, yet members with sleep apnea or cardiovascular disease may still gain coverage for Wegovy or Zepbound through a formulary exception. Here is exactly how to check your plan, file an appeal, and compare the lowest cash-pay prices if insurance says no.
Humana Medicare Advantage plans generally do not cover Wegovy or Zepbound when they are prescribed solely for obesity, because Medicare Part D law still excludes drugs “used for weight loss.” However, many Humana plans will consider an exception when these GLP-1s are prescribed to cut cardiovascular risk or treat obesity-related conditions such as sleep apnea. If your request is denied, you can appeal, use manufacturer savings programs, or pay the predictable mail-order cash prices from NovoCare or LillyDirect.
- The list price for Wegovy is $1,349.02 for a 28-day pen pack, while Zepbound lists at $1,269.50 for the same amount (Novo Nordisk, Eli Lilly).
- Medicare Part D statutes still exclude drugs “for weight loss,” but plans can grant case-by-case exceptions for other FDA-approved indications (CMS).
- Humana requires prior authorization and often proof of cardiovascular disease, stroke, or obstructive sleep apnea before it will approve Wegovy or Zepbound coverage.
- A formulary exception decision must be issued within 72 hours (24 hours if expedited) after Humana receives your prescriber’s supporting statement (Humana).
- NovoCare caps Wegovy self-pay at $999 per 28-day shipment, and LillyDirect caps Zepbound self-pay at $950, both shipped directly to your home.
What Wegovy and Zepbound Are
Wegovy and Zepbound are once-weekly injectable GLP-1 receptor agonists approved by the FDA for chronic weight management in adults with obesity or overweight plus at least one weight-related condition. The active ingredient in Wegovy is semaglutide, and Zepbound contains tirzepatide. Both lower appetite, slow stomach emptying, and improve insulin sensitivity, which together promote clinically meaningful weight loss.
Besides weight management, Wegovy holds an FDA indication to reduce cardiovascular events in adults with obesity and established cardiovascular disease. Zepbound’s manufacturer is pursuing a similar claim but has not yet received approval as of October 2026. These non-weight-loss indications matter because they can open the door to Medicare Part D coverage.
Does Humana Medicare Advantage Cover Them?
Most Humana Medicare Advantage and Part D plans list Wegovy and Zepbound as “non-covered” for weight loss, but individual plans may approve them under specific medical criteria. Humana publishes separate pharmacy and medical policy documents. The current pharmacy policy tags both drugs as “excluded under the Part D weight-loss clause” when obesity is the only diagnosis. Yet the same document says a coverage determination may be granted if the prescription is for:
- Cardiovascular risk reduction in patients with previous heart attack, stroke, or symptomatic peripheral arterial disease.
- Treatment of moderate-to-severe obstructive sleep apnea confirmed by a sleep study.
- Type 2 diabetes that is poorly controlled on metformin and lifestyle changes, in the case of Zepbound’s sister diabetes drug Mounjaro.
Because Humana sells dozens of Medicare Advantage plans, you or your prescriber must verify your exact plan’s formulary or call the plan’s pharmacy benefit number on the back of your Member ID card.
When Exceptions Apply
An exception is a formal request asking Humana to cover a drug that is normally excluded. Federal rules allow exceptions when the drug is medically necessary and no preferred alternative is suitable. For Wegovy or Zepbound, common exception scenarios include:
Cardiovascular disease: The SELECT trial showed Wegovy lowered the risk of major cardiovascular events by 20 percent in people with obesity and prior heart disease (fda.gov). Your cardiologist can cite this indication when requesting coverage.
Obstructive sleep apnea: Weight loss of 10 percent can improve apnea-hypopnea index scores. If you fail or cannot tolerate CPAP, your pulmonologist may seek GLP-1 coverage as adjunct therapy.
Mobility-limiting osteoarthritis: Some plans accept severe joint disease as a “functional impairment” that justifies weight-management pharmacotherapy.
How to File an Exception or Appeal
Your prescriber must start the process by submitting a Coverage Determination Request (Form CMS-10146) to Humana. Humana accepts the form by fax or through electronic prior authorization (ePA). Key steps:
1. Gather evidence: Your doctor attaches chart notes, lab results, sleep study reports, or cardiology consults that prove the FDA-approved non-weight-loss indication.
2. Submit: The form asks whether the request is standard (decision within 72 hours) or expedited (within 24 hours).
3. Track the answer: Humana notifies both you and the prescriber. If denied, you can request a redetermination within 60 days, and a second-level Independent Review Entity will decide within 7 days.
Do you meet Humana's GLP-1 exception criteria?
Check the column that fits your situation:
✅ Likely to qualify
- BMI ≥ 30 and documented cardiovascular disease
- Moderate-to-severe obstructive sleep apnea with CPAP intolerance
- Two failed trials of anti-obesity medications on the plan formulary
- Specialist letter of medical necessity attached
🏥 Needs more documentation
- BMI ≥ 30 with no obesity-related complications documented
- Request written only by the patient, no prescriber statement
- Desire for cosmetic weight loss
- Trial of covered alternatives never attempted
Other Ways to Afford Wegovy or Zepbound
If Humana’s final answer is no, you still have three main payment paths.
Manufacturer savings cards: NovoCare and Eli Lilly offer copay cards for people with commercial insurance, but Medicare rules block their use. However, if you pay the full cash price outside Part D, the card can sometimes be applied. Confirm with the pharmacy.
NovoCare mail order: Novo Nordisk sells Wegovy directly to patients for $999 per 28-day shipment. The price is the same at any dose, shipping is free, and you can pause or cancel at any time.
LillyDirect mail order: Eli Lilly sells Zepbound for $950 per 28-day shipment, also dose-independent with free delivery.
Medicare GLP-1 Bridge: If you recently lost commercial coverage and are in the first 36 months of Medicare, you may qualify for the CMS Obesity Drug Bridge Demonstration that subsidizes GLP-1s for up to 24 months (CMS Innovation Center). Ask your prescriber to enroll you.
If you decide to pay cash, compare local pharmacy coupons on Rx.com or order the drug directly through NovoCare or LillyDirect for predictable pricing.
Cost Comparison Table
| Source | Price per 28-day supply | Fine print |
|---|---|---|
| Average retail pharmacy | $1,350 (Wegovy) / $1,270 (Zepbound) | Price varies by chain; coupons may lower. |
| NovoCare Home Delivery | $999 (flat) | Ships nationwide, cancel anytime. |
| LillyDirect Home Delivery | $950 (flat) | Ships nationwide, cancel anytime. |
| Humana Part D tier 3 preferred brand copay | $47-$100 | Only if exception approved. |
When to Contact Your Doctor
GLP-1 medications are generally safe, but serious side effects can occur.
🚨 When to Contact Your Healthcare Provider
Contact your doctor immediately if you experience any of the following:
- Severe abdominal pain: could signal pancreatitis.
- Persistent vomiting or inability to keep liquids down: risk of dehydration and kidney injury.
- Vision changes: possible diabetic retinopathy progression.
- A lump or swelling in the neck: very rare but may suggest thyroid tumor.
- Sudden shortness of breath or chest pain: could indicate a cardiovascular event.
- Signs of low blood sugar (shakiness, confusion), especially if taking insulin or sulfonylureas.
- Thoughts of self-harm or sudden mood changes, call or text the Suicide & Crisis Lifeline at 988, available 24 hours a day.
Scientific References
- Welcome to Novo in the U.S. | Novo U.S. Website. novonordisk-us.com.
- Just a moment. lilly.com.
- Home: Centers for Medicare & Medicaid Services | CMS. cms.gov.
- Humana | Find Medicare Plans and Health Insurance Coverage. humana.com.
- U.S. Food and Drug Administration. fda.gov.
- Overview: CMS Innovation Center | CMS. innovation.cms.gov.
Frequently Asked Questions
Does any Medicare Advantage plan routinely cover Wegovy or Zepbound in 2026?
No. As of October 2026, all major Medicare Advantage carriers, including Humana, treat weight-loss GLP-1s as excluded drugs unless the member qualifies for a medical exception based on another FDA-approved indication.
What documents does Humana need for a Wegovy cardiology exception?
Your cardiologist should provide hospital discharge summaries, stress test results, or echocardiogram reports confirming prior myocardial infarction, stroke, or symptomatic peripheral artery disease, plus a note explaining why GLP-1 therapy is medically necessary.
Can I ask Humana to cover a smaller starter pack first?
Possibly. Some plans approve a four-pen starter kit to assess tolerance before authorizing ongoing therapy. Your prescriber must request it in the prior authorization notes.
Will using a manufacturer savings card violate Medicare rules?
Yes. Federal anti-kickback law bars manufacturer assistance from being used toward Medicare cost-sharing. You may, however, waive Part D billing and pay the full cash price outside the benefit, then the card may apply. Confirm with your pharmacy’s billing department.
How long does a Humana coverage determination take?
Standard requests require a decision within 72 hours of receiving your prescriber’s statement. If your health is at serious risk without the drug, an expedited request must be answered within 24 hours.
Can I switch from Humana to another Medicare Advantage plan that covers GLP-1s?
Maybe. Plan formularies reset each January 1. During the Medicare Open Enrollment Period (October 15 to December 7) you can compare plans and switch. Check each plan’s 2027 formulary before enrolling.
Does Humana cover diabetes-only GLP-1 drugs like Ozempic?
Yes, most Humana Part D formularies list Ozempic as a preferred brand for type 2 diabetes. Coverage rules differ because Ozempic’s primary indication is glycemic control, not weight loss.
